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Hand grip strength (HGS) and the 2-minute walk test (2MWT) have been proposed as elements of chronic
graft-versus-host disease (GVHD) assessment in clinical trials. Using all available data (n ¼ 584 enrollment
visits, 1689 follow-up visits, total of 2273 visits) from a prospective observational cohort study, we explored
the relationship between HGS and 2MWT and patient-reported measures (Lee symptom scale, MOS 36-Item
Short-Form Health Survey [SF-36], and Functional Assessment of Cancer Therapy [FACT]-Bone Marrow
Transplantation quality of life instruments and Human Activity Proﬁle [HAP]), chronic GVHD global severity
(National Institutes of Health global score, clinician global score, and patient-reported global score), calcu-
lated and clinician-reported chronic GVHD response, and mortality (overall survival, nonrelapse mortality,
and failure-free survival) in multivariable analyses adjusted for signiﬁcant covariates. 2MWT was signiﬁcantly
associated with intuitive domains of the Lee Symptom Scale (overall, skin, lung, energy), SF-36 domain and
summary scores, FACT summary and domain scores, and HAP scores (all P < .001). Fewer associations were
detected with the HGS. The 2MWT and HGS both had signiﬁcant association with global chronic GVHD
severity. In multivariable analysis, 2MWT was signiﬁcantly associated with overall survival, nonrelapse
mortality, and failure-free survival, whereas no association was found for HGS. 2MWT and HGS were not
sensitive to National Institutes of Health or clinician-reported response. Based on independent association
with mortality, these data support the importance of the 2MWT for identiﬁcation of high-risk chronic GVHD
patients. However, change in 2MWT is not sensitive to chronic GVHD response, limiting its usefulness in
clinical trials.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Chronic graft-versus-host disease (GVHD) is an important
source of mortality, impaired quality of life (QOL), disability,
and prolonged duration of immune suppression after allo-
geneic hematopoietic cell transplantation (HCT) [1-6].
Following a National Institutes of Health (NIH) consensus
conference, a series of expert opinionebased recommenda-
tions aimed to standardize diagnosis, scoring, histopa-
thology, biomarkers, response assessment, and the conduct
of clinical trials in chronic GVHD [7-12]. Among the proposed
measures for assessing chronic GVHD were the 2-minute
walk test (2MWT) and hand grip strength (HGS).
Measures of exercise tolerance have been used inmultiple
settings to diagnose impairment, tomonitor change in ability
over time and with interventions, and to estimate prognosis.
One of the most widely used is the 6-minute walk test [13],
which has been studied in several cardiopulmonarydgment on page 972.
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13.03.014conditions, including chronic obstructive pulmonary disease
[14], pulmonary artery hypertension, interstitial lung
disease, and congestive heart failure [15], and in cardiopul-
monary rehabilitation [16]. Most studies demonstrate that
this test is valid, reliable, and responsive to change. Impaired
performance has been associated with mortality in the
setting of chronic obstructive pulmonary disease [17], end-
stage renal disease [18], and congestive heart failure [15].
Walking speed has also been associated with all-cause
mortality among older community-dwelling adults [19].
Similarly, the 2MWT has been validated in chronic obstruc-
tive pulmonary disease [20], but little information exists
regarding the utility of this measure after HCT [21]
The HGS test, a measure of voluntary muscle function, has
been studied as an indicator of muscle mass and nutritional
status. Multiple studies have demonstrated an association
between disease-relatedmalnutrition and grip strength [22].
Impaired HGS has been associated with increased risk for
postoperative complications, lower functional status,
hospital readmission rates, functional limitations and
disability [22], and overall mortality among healthy and
older adults [19] and those with chronic illness, including
chronic kidney disease [23,24]. Although HGS has beenTransplantation.
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after HCT and in the setting of acute GVHD [25], HGS has not
been previously studied in the setting of chronic GVHD.
In summary, allied literature supports the 2MWTandHGS
as important measures of physiologic reserve and vulnera-
bility in both healthy adults and those with chronic medical
conditions. We examined these recommended measures
among chronic GVHD-affected HCT recipients to determine
their association with patient-reported measures, chronic
GVHD severity, chronic GVHD response, and mortality.
METHODS
Chronic GVHD Cohort
The Chronic GVHD Consortium developed a multicenter observational
cohort study of chronic GVHD-affected HCT recipients [26]. This cohort
included subjects who were allogeneic HCT recipients age 2 years with
chronic GVHD requiring systemic immunosuppressive therapy [8]. Cases are
classiﬁed as incident (enrollment <3 months after chronic GVHD diagnosis)
or prevalent (enrollment 3months after chronic GVHD diagnosis but
<3 years after transplantation). Exclusion criteria include primary disease
relapse and inability to comply with study procedures.
Clinicians and patients report standardized information on chronic
GVHD organ involvement and symptoms at cohort enrollment and at serial
follow-up visits (every 6 months for prevalent cases versus at 3 months,
then every 6 months for incident cases). Chronic GVHD global severity
according to the NIH Chronic GVHD Consensus is scored according to
objective criteria for each organ involved, which is summarized for an
overall score of mild, moderate, or severe [8]. Additional measures examine
the impact of chronic GVHD on functional ability, symptom burden, and
QOL. The assessments performed reﬂect the recommendations of the NIH
Consensus Conference.
HGS and 2MWT
Functional measures examined in this analysis were standardized HGS
and the 2MWT. In the assessment of HGS, strength was measured 3 times
from the dominant hand using a portable electronic dynamometer [10,27].
In the conduct of the 2MWT, the patient was instructed to walk a 50-foot
course (25 feet each direction) with 180-degree turns at each end, and the
total distance covered in 2 minutes was recorded [10,21,28].
Patient Reported Measures
The Lee Chronic GVHD Symptom Scale is a 30-item, 7-subscale symptom
scale that evaluates adverse effects of chronic GVHD on skin, vitality, lung,
nutritional status, psychological functioning, eye, and mouth symptoms
[29]. The Human Activity Proﬁle (HAP) is a 94-item self-reported assessment
of energy expenditure and physical ﬁtness. The instrument was ﬁrst
developed in a population with pulmonary disease and has since been
validated in an HCT population [30,31]. Respondents indicate whether they
never did, have stopped, or are still performing listed activities. A maximum
activity score, adjusted activity score, and modiﬁed adjusted activity score
are calculated.
The Functional Assessment of Cancer Therapy-Bone Marrow Trans-
plantation (FACT-BMT), version 4.0, is a 37-item self-report questionnaire that
includes a 10-item BMT subscale. The instrument measures the effect of
cancer therapy onmultipleQOLdomains including physical (PWB), functional
(FWB), social/family, emotional well-being, and BMT-speciﬁc concerns. Indi-
vidual domain scores can be summarized to give a total FACT-BMT score
(including all subscales) or a FACT-TOI (PWB þ FWB þ BMT subscale) [32,33].
The MOS 36-Item Short-Form Health Survey (SF-36), version 2, is
a 36-item self-report questionnaire that assesses health and functioning.
The instrument examines the following domains: physical functioning, role
functioning-physical, bodily pain, general health, vitality, social functioning,
role functioning-emotional, and mental health. Two summary scales from
the SF-36 include the Physical Component Score and theMental Component
Score [34-37].
Statistical Methods
Patient, transplantation, and chronic GVHD characteristics of the study
subjects were summarized with descriptive statistics, including median and
range or frequencies and percentages according to the nature of the data. All
available cohort data (through March 31, 2012) from enrollment and serial
follow-up visits were used for these analyses. Grip strength data was
adjusted for gender, age, and grip position, as recommended [38].
To account for within-patient correlation, linear mixed models with
random patient effects were used for continuous outcomes, and the
generalized estimating equations were used for binary outcomes.Considering multiple testing, Type I error was controlled by treating a two-
sided P < .01 as statistically signiﬁcant. Logistic regression models with
generalized estimating equation method were used to assess whether
missing 2MWT or HGS data were associated with patient, disease, or
transplantation characteristics.
For the analysis of symptom scale, with QOL and HAP measures as
outcomes,multivariable linearmixedmodelswere constructed using all visit
data. The variables of 2MWT and HGS were put in the same model, while
adjusting for signiﬁcant covariates, including patient age at HCT (<50,
higher), patient gender, patient education level (high school or lower, college
level, graduate school level, missing), month from HCT to cohort enrollment
(<12months, higher), donorepatient gender combination (female intomale,
other), Karnofsky performance status (<80, 80þ, missing), platelet count
(<100K, higher), NIH global severity (less than mild, moderate, severe),
bilirubin (2, higher), and overlap versus classic chronic GVHD status.
In the analysis of 2MWT and HGS with global chronic GVHD severity,
linear mixed models were used to study the association between these
functional measures and 3 different global severity scores: NIH global 0 to 3
severity score, clinician-reported overall 0 to 3 severity score, and patient-
reported overall 0 to 3 severity score. The association between binary
individual organ sites of chronic GVHD involvement and 2MWT and HGS
was also investigated using logistic regression models with generalized
estimating equations method. Individual organ involvement was deﬁned by
clinician report. Adjusted covariates included patient age at transplantation
(<50, higher), patient gender, month from HCT to cohort enrollment
(<12 months, higher), donorepatient gender combination (female into
male, other), Karnofsky performance status (<80, 80þ, missing), case type
(incident, prevalent), platelet count (<100K, higher), study site (Fred
Hutchinson Cancer Research Center [FHCRC], other), and overlap versus
classic chronic GVHD type.
In addition, using linear mixed models, we studied the association
between change in HGS and 2MWTwith chronic GVHD response (both NIH-
calculated response and clinician-reported response categories) at 6 months
from cohort enrollment. NIH organ speciﬁc (skin, eye, mouth, gastrointes-
tinal [GI], liver, lung) and overall responses were deﬁned by the provisional
algorithms proposed at the 2005 NIH Consensus Conference [10]. Clinician-
reported responses were complete response, partial response, stable
disease, or progressive disease. Change in HGS and 2MWT was studied with
respect to the response categories of complete response/partial response
versus stable disease/progressive disease and also complete response versus
partial response/stable disease/progressive disease.
As well, we studied the relationship between clinically meaningful
change (deﬁned as .5 standard deviation change) in 2MWT and HGS and
the 6-month response (in 3 categories, namely response [complete
response/partial response], stable disease, and progression) using the
gamma statistic, which measures concordance between ordinal categorical
measures. This statistic ranges from 1 to 1, with value <.4 considered poor
concordance empirically.
Finally, multivariable Cox regression was performed to study the asso-
ciation between 2MWT and HGS with overall survival (OS), nonrelapse
mortality (NRM), and failure-free survival (FFS). NRM was deﬁned as death
without prior relapse. OS was calculated from the time of enrollment, with
patients censored at date last known alive. For the calculation of FFS, events
included death, relapse, or use of additional systemic immune suppressive
therapy (includedas anobjectivemeasure of chronicGVHD treatment failure).
Separate models were constructed to evaluate only cohort enrollment data
and then all available data in a time-varying model. In separate analyses, we
explored both quartile andmedian cut points in the 2MWT data to determine
a threshold for increased mortality. Change in 2MWT and HGS at 6 months
was tested for correlationwith subsequent OS and NRM. In survival analyses,
covariates included study site (FHCRC, other), case type (incident, prevalent),
month from HCT to cohort enrollment (<12 months, higher), platelet count
(<100K, higher), Karnofsky performance status (<80, 80þ, missing), patient
age at transplantation (<50 versus higher), donor match relation (matched
related, matched unrelated, mismatched), donorepatient gender combina-
tion (female into male versus other), transplantation type (myeloablative
versus not), bilirubin (2, higher), NIH global severity (less than mild,
moderate, severe), and overlap versus classic chronic GVHD type.
Statistical analyses were performed with SAS/STAT software, version 9.3
(SAS Institute, Inc., Cary, NC) and R version 2.15.2 (R Foundation for Statis-
tical Computing, Vienna, Austria).RESULTS
Patient Characteristics
A total of 584 individual patients (1689 follow-up visits,
total of 2273 visits) contributed data to the analysis. The
cohort included both incident and prevalent cases and
Table 1
Cohort Characteristics at Study Enrollment (n ¼ 584)
Characteristics Category n Count (%) Median Min Max
Study site FHCRC 584 254 (43%)
University of Minnesota 61 (10%)
Dana-Faber Cancer institute 65 (11%)
Stanford University Medical Center 73 (13%)
Northwest Children’s Hospital 13 (2%)
Vanderbilt University Medical Center 47 (8%)
Medical College of Wisconsin 23 (4%)
Washington University Medical Center 4 (1%)
Mofﬁtt Cancer Center 39 (7%)
Memorial Sloan-Kettering Cancer Center 5 (1%)
Case type Incident 584 346 (59%)
Prevalent 238 (41%)
Adults or children Adults 584 570 (98%)
Children 14 (2%)
Patient age at cohort registration, yr 584 51.5 2 79
Patient gender Female 584 248 (42%)
Male 336 (58%)
Months from transplant to cGVHD onset 584 7.3 1.2 291
Months from cGVHD onset to enrollment 584 1.8 0 32.5
Diagnosis AML 584 194 (33%)
ALL 69 (12%)
CML 30 (5%)
CLL 46 (8%)
MDS 88 (15%)
NHL 84 (14%)
HD 17 (3%)
MM 29 (5%)
AA 7 (1%)
Other 20 (4%)
Disease status Early 580 190 (33%)
Intermediate 247 (42%)
Advanced 143 (25%)
Transplant source Bone marrow 584 40 (7%)
Cord blood 28 (5%)
Peripheral blood 516 (88%)
Transplant type Myeloablative 581 334 (57%)
Nonmyeloablative 247 (43%)
Donorepatient CMV status Patient and donor CMV both negative 578 195 (34%)
Patient or donor CMV positive 383 (66%)
Donorepatient gender combination Female into male 578 168 (29%)
Others 410 (71%)
Donor match Matched related 582 243 (42%)
Matched unrelated 244 (42%)
Mismatched 95 (16%)
Prior acute GVHD Have prior acute GVHD 584 384 (66%)
No prior acute GVHD 200 (34%)
Karnofsky performance score 80þ 584 309 (53%)
<80 184 (31%)
Missing 91 (16%)
Total serum bilirubin, mg/dL 2 579 549 (95%)
>2 30 (5%)
Platelet count, /mL <100 581 91 (16%)
100 490 (84%)
NIH 0-3 cGVHD global severity score None 584 3 (1%)
Mild 50 (8%)
Moderate 304 (52%)
Severe 227 (39%)
Clinician 0-3 cGVHD severity score None 583 1 (<1%)
Mild 271 (46%)
Moderate 250 (43%)
Severe 61 (10%)
Patient 0-3 cGVHD severity score None 487 13 (3%)
Mild 251 (51%)
Moderate 181 (37%)
Severe 42 (9%)
Walk test (feet) 492 500 170 1150
Grip strength (lb) 546 60 2 167
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, mye-
lodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin lymphoma; MM, multiple myeloma; AA, aplastic anemia; CMV, cytomegalovirus; cGVHD,
chronic GVHD.
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characteristics are represented in Table 1. Among patient
characteristics studied, those with any missing 2MWT dataweremore likely to have Karnofsky performance status<80%
(P < .001) and greater NIH global chronic GVHD severity
(P ¼ .02). Those enrolled at FHCRC were less likely to have
Table 3
Site of Chronic GVHD Organ Involvement: Association with 2MWT and HGS
Measure n Effect P Odds 95% 95%
J. Pidala et al. / Biol Blood Marrow Transplant 19 (2013) 967e972970missing HGS data (P < .001). Other variables did not differ
according to the presence or absence of missing 2MWT or
HGS data.Ratio* Lower CI Upper CI
Skin involvement 1717 2MWT .36 1.00 .998 1.001
HGS .02 .99 .981 .998
Mouth involvement 1716 2MWT .96 1.00 .999 1.001
HGS .27 1.01 .996 1.013
Eye involvement 1718 2MWT .58 1.00 .999 1.001
HGS .46 1.003 .996 1.010
GI involvementy 1732 2MWT <.001 .997 .996 .998
HGS .06 .992 .983 1.000
Liver involvementy 1727 2MWT <.001 .998 .997 .999
HGS .74 .999 .992 1.006
Joint involvement 1718 2MWT .84 1.00 .999 1.001
HGS .20 .994 .985 1.003
Genital involvement 1575 2MWT .03 1.002 1.00 1.004
HGS .07 .986 .97 1.001
Lung involvement 1718 2MWT .003 .998 .997 .999
HGS .41 1.004 .995 1.013
* Odds ratio represents the likelihood of organ involvement (clinician-
reported organ involvement on 0-3 score of >0) in relationship to change in
either 2MWT or HGS. For example, in the case of lung involvement: As
2MWT increases by 1 foot, the odds of lung involvement decreases by .2%
(odds ratio of .998).
y Models adjusting for background variables for GI and liver were not
estimable, so models without adjusting for background variables for these
organs are reported.Patient-Reported Measures
In multivariable analysis adjusting for signiﬁcant clinical
covariates, the shorter 2MWT was still associated with
higher Lee Chronic GVHD Symptom Scale overall, skin, lung,
and energy domains (all P < .001). Among the studied QOL
measures, 2MWT was also associated with the SF-36
instrument Physical Component Score, physical func-
tioning, role functioning-physical, general health, and
vitality (all P < .001), but not with the Mental Component
Score. Similarly, there was signiﬁcant association between
2MWT and the FACT instrument FACT-G, FACT-TOI, FACT-
BMT, PWB, and FWB (all P < .001). Association was also
found between 2MWT and the HAP scores, including
maximum activity score, adjusted activity score, and modi-
ﬁed adjusted activity score (all P < .001).
In contrast, fewer associations were detected in the case
of the HGS: None of the Lee Chronic GVHD Symptom Scale
domains met the speciﬁed P < .01 level of signiﬁcance.
Among the studied QOL instruments, HGS was associated
with the SF-36 physical component score summary score
(P ¼ .002) and general health (P ¼ .002) and with the FACT
instrument FACT-TOI (P ¼ .002), FACT-BMT (P ¼ .008), and
FWB (P< .001). Among HAP scores, only the adjusted activity
score had signiﬁcant association with HGS (P ¼ .005).Chronic GVHD Severity and Organ Involvement
As presented in Table 2, the 2MWT had signiﬁcant asso-
ciationwith global severity according to NIH global score and
clinician- and patient-reported chronic GVHD severity.
Patients with NIH global score of less than mild or mild and
moderate achieved on average 20.7 and 15.3 feet greater
distance compared with those with NIH severe chronic
GVHD. This effect was even more striking for clinician- and
patient-reported global chronic GVHD severity. In addition,
signiﬁcant associations were detected for each in the case of
HGS.Table 2
Association of 2MWT and HGS with Chronic GVHD Global Severity Score
Measure Severity Group n P Estimate* 95%
Lower
CI
95%
Upper
CI
2MWT NIH None/mild 302 .005 20.74 6.38 35.10
NIH Moderate 971 .004 15.27 4.83 25.70
NIH Severe 505 0
2MWT Clinician None/mild 1089 <.001 37.86 19.46 56.26
Clinician Moderate 561 .006 25.12 7.25 43.00
Clinician Severe 122 0
2MWT Patient None/mild 945 <.001 66.12 43.95 88.29
Patient Moderate 424 .001 38.11 15.95 60.27
Patient Severe 83 0
HGS NIH None/mild 327 .005 2.10 .63 3.58
NIH Moderate 1111 <.001 2.33 1.24 3.41
NIH Severe 599 0
HGS Clinician None/mild 1233 <.001 3.80 1.96 5.63
Clinician Moderate 645 .23 1.17 .75 3.09
Clinician Severe 152 0
HGS Patient None/mild 1052 <.001 4.39 2.10 6.69
Patient Moderate 487 .005 3.47 1.06 5.88
Patient Severe 98 0
* Estimates represent additional feet (2MWT) or pounds (HGS) achieved
with reference to severe chronic GVHD group for each comparison.Impaired performance in the 2MWT was associated with
higher odds of GI, liver, and lung involvement (Table 3).
Conversely, no individual sites of chronic GVHD involvement
met the P < .01 signiﬁcance level in association with HGS. As
a separate approach, we also examined the relationship
between 2MWT and HGS and the designation of either
single-organ or multiple-organ site involvement with
chronic GVHD. Of 2273 total visits, the majority (n ¼ 1895)
had multiple-organ involvement, whereas less (n¼ 365) had
single-organ involvement (13 missing). Univariable logistic
regression models showed that greater 2MWT had lower
odds of multiple-organ involvement (P ¼ .15), and a similar
trend was observed for the HGS (P ¼ .36), but the association
was not statistically signiﬁcant.
Change in HGS and 2MWT: Association with Chronic
GVHD Response
No signiﬁcant associations were detected between
change in HGS or 2MWT and either the NIH-calculated or
clinician-reported chronic GVHD response at 6 months from
cohort enrollment. Similarly, no signiﬁcant associations were
detected when individual organ responses were studied. In
our analysis of clinically meaningful change, most patients
had stable disease, namely no clinically meaningful
improvement or worsening in 2MWT or HGS (Table 4). Both
2MWT and HGS demonstrated poor concordance with
6-month NIH response (both overall response and individual
organ responses) and 6-month clinician-reported overall
response (all had gamma statistic <.4).
Survival and NRM
As demonstrated in Table 5, greater distance achieved in
the 2MWT was signiﬁcantly associated with reduced hazard
for death. This conclusion held true both for both OS and
NRM outcomes and also in separate models based on
enrollment data alone or using all data in a time-varying
model. Results were similar for the endpoint of FFS. In
subsequent analyses, we explored quartile and median cut-
points in the observed 2MWT data to discern a threshold
Table 4
Summary of Clinically Meaningful Change in 2MWT and HGS from Cohort
Enrollment to 6 Months
Measure % Increase
>.5 SD
% Stable % Decrease
>.5 SD
Gamma
2MWT
NIH overall response 22 63 15 .08
NIH skin response 23 64 13 .21
NIH eye response 22 66 12 .22
NIH mouth response 25 64 11 .04
NIH GI response 28 58 14 .17
NIH liver response 24 61 15 .09
Clinician reported response 22 63 15 .01
HGS
NIH overall response 32 44 24 .20
NIH skin response 35 42 23 .15
NIH eye response 30 50 20 .09
NIH mouth response 35 42 23 .009
NIH GI response 35 36 29 .39
NIH liver response 30 43 27 .19
Clinician reported response 32 44 24 .09
Table 5
Survival Outcomes: Association of 2MWT and HGS with OS and NRM
Outcome Measure P Hazard Ratio* 95% CI
At enrollment
OS 2MWT .002 .996 .994 .999
HGS .95 .999 .983 1.017
NRM 2MWT .003 .996 .993 .999
HGS .87 1.002 .981 1.023
FFS 2MWT .07 .999 .998 1.000
HGS .28 1.006 .995 1.016
Time varying
OS 2MWT <.001 .995 .993 .998
HGS .63 .994 .969 1.019
NRM 2MWT .001 .994 .991 .998
HGS .95 .999 .967 1.032
FFS 2MWT .01 .998 .997 1.000
HGS .76 1.002 .991 1.013
2MWT grouped as 500 vs. >500
Outcome Group P Hazard Ratio 95% CI
At enrollment
OS 500 .10 1.51 .93 2.45
>500 1
NRM 500 .05 1.93 1.00 3.72
>500 1
FFS 500 .10 1.24 .96 1.59
>500 1
Time varying
OS 500 .002 2.58 1.41 4.73
>500 1
NRM 500 .02 2.55 1.17 5.56
>500 1
FFS 500 .008 1.42 1.10 1.85
>500
* Hazard ratio for OS or NRM according to increase in the functional test
(2MWT or HGS) by one unit.
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signiﬁcantly increased hazard for mortality, and this effect
was most pronounced in the time-varying model (Table 5).
Change in 2MWT or HGS after 6 months was not associated
with subsequent OS or NRM.
DISCUSSION
Valid, safe, and practical methods for assessing functional
impairment and vulnerability among chronic GVHD-affected
HCT patients are needed. Measures of exercise tolerance and
voluntary muscle strength have proven useful in other
chronic health conditions. We examined whether the 2MWT
and HGS measures recommended by the NIH Consensus
Conference were associated with patient-reported measures,
chronic GVHD severity, chronic GVHD response, and
mortality.
The major ﬁnding from this analysis is the independent
association of the 2MWT with mortality among chronic
GVHD-affected HCT patients. This important effect was dis-
cerned, independent of relevant patient, disease, and trans-
plantation covariates (including chronic GVHD global
severity). Beyond this major ﬁnding, impaired 2MWT was
signiﬁcantly associated with higher symptom burden,
impaired QOL across multiple domains, functional disability
assessed by the HAP instrument, and increased mortality.
Although the exact cause of impaired performance on the
walk test is largely not known among chronic GVHD patients,
it likely represents the combined burden of reduced cardio-
pulmonary ﬁtness, impaired function in chronic GVHD target
organs, decreasedmuscle strength, a multifactorial volitional
component (as it is a self-paced test), and the impact of
immune-suppressive therapies (eg, muscle atrophy and
dependent edema related to systemic glucocorticoid
therapy). Interestingly, GI, liver, and lung involvement were
identiﬁed as particularly important among this chronic
GVHD cohort. This may reﬂect both direct contributions of
organ involvement and impact from systemic immune-
suppressive therapy.
We could not, however, demonstrate that change in
2MWT (including clinically meaningful change) has a signif-
icant association with calculated or clinician-reported
chronic GVHD response. Because change in 2MWT (or
HGS) is not sensitive to chronic GVHD response, these
measures do not have a role in assessing response intherapeutic trials or clinical practice. As well, change in
2MWT (and HGS) did not have an association with subse-
quent mortality, further consolidating this ﬁnding. Rather,
the 2MWT appears to be useful to describe the type of
patients who enroll in a study and to place their underlying
mortality risk in context.
The data largely do not support the importance of the
HGS among chronic GVHD patients. Although HGS has an
association with some QOL summary scores, HAP- adjusted
activity score, and global chronic GVHD severity, there was
no signiﬁcant association with mortality and no association
with chronic GVHD response. The lack of association with
mortality in this cohort diverges from published data that
support the HGS as predictive of overall and cause-speciﬁc
mortality among healthy adults, elderly, and within certain
chronic illness groups [19,22-24]. Based on the available data
in the cohort study, we cannot address other important
outcomes previously reported in allied literature, such as
treatment complications, hospital readmission rates, or
nutritional endpoints [22].
The large sample size of the cohort and prospectively
acquired data bring strength to this analysis. However, we
offer the following limitations. First, these two measures do
not encompass the range of available approaches for
assessing functional impairment. Alternative methods such
as the 6-minute walk test or more sophisticated technology
such as cardiopulmonary exercise testing may provide
additional information. Interestingly, a previous analysis has
shown signiﬁcant correlation between HGS and a more
involvedmeasurement of isometric muscle strength inmajor
muscle groups of the upper extremity among patients after
HCT [25]. As well, integration of such functional measures
J. Pidala et al. / Biol Blood Marrow Transplant 19 (2013) 967e972972and other estimates of frailty and comorbidity may enhance
ability to detect those at risk. Further study is needed in this
regard.
In conclusion, these data support that the 2MWT is
associated with patient-reported measures, chronic GVHD
severity, and mortality. However, it is not sensitive to chronic
GVHD response. The data do not support the ongoing use
of HGS.
ACKNOWLEGMENT
Financial disclosure: Supported by grant CA 118953
(principle investigator, S.J.L.) and NIAID U54 AI 083028
(principle investigator, S.J.L.).
REFERENCES
1. Arai S, Jagasia M, Storer B, et al. Global and organ-speciﬁc chronic graft-
versus-host disease severity according to the 2005 NIH Consensus
Criteria. Blood. 2011;118:4242-4249.
2. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-
host disease. Hematol Am Soc Hematol Educ Progr. 2008;134-141.
3. Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic
cell transplantation. Blood. 2009;114:7-19.
4. Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is
associated with severity of chronic graft-versus-host disease as
measured by NIH criteria: report on baseline data from the Chronic
GVHD Consortium. Blood. 2011;117:4651-4657.
5. Pidala J, Kurland B, Chai X, et al. Sensitivity of changes in chronic graft
vs. host disease activity (measured by National Institute of Health
global severity, clinician, and patient assessment) to changes in
patient-reported quality of life: results from the chronic graft vs. host
disease Consortium. Haematologica. 2011;96:1528-1535.
6. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive
treatment for chronic graft-versus-host disease. Blood. 2004;104:
3501-3506.
7. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and
supportive care of chronic graft-versus-host disease: National Insti-
tutes of Health consensus development project on criteria for clinical
trials in chronic graft-versus-host disease. V. Ancillary Therapy and
Supportive Care Working Group Report. Biol Blood Marrow Transplant.
2006;12:375-396.
8. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. I. Diagnosis and staging working group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
9. Martin PJ, Weisdorf D, Przepiorka D, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. VI. Design of Clinical Trials Working Group
Report. Biol Blood Marrow Transplant. 2006;12:491-505.
10. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in
chronic graft-versus-host disease: National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. IV. Response Criteria Working Group Report.
Biol Blood Marrow Transplant. 2006;12:252-266.
11. Schultz KR, Miklos DB, Fowler D, et al. Toward biomarkers for chronic
graft-versus-host disease: National Institutes of Health consensus
development project on criteria for clinical trials in chronic graft-
versus-host disease. III. Biomarker Working Group Report. Biol Blood
Marrow Transplant. 2006;12:126-137.
12. Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic diagnosis of
chronic graft-versus-host disease: National Institutes of health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease. II. Pathology Working Group Report. Biol
Blood Marrow Transplant. 2006;12:31-47.
13. Rasekaba T, Lee AL, Naughton MT, et al. The six-minute walk test:
a useful metric for the cardiopulmonary patient. Intern Med J. 2009;39:
495-501.
14. Kocks JW, Asijee GM, Tsiligianni IG, et al. Functional status measure-
ment in COPD: a review of available methods and their feasibility in
primary care. Prim Care Respir J. 2011;20:269-275.15. Arslan S, Erol MK, Gundogdu F, et al. Prognostic value of 6-minute walk
test in stable outpatients with heart failure. Tex Heart Inst J. 2007;34:
166-169.
16. Bellet RN, Adams L, Morris NR. The 6-minute walk test in outpatient
cardiac rehabilitation: validity, reliability and responsiveness-
a systematic review. Physiotherapy. 2012;98:277-287.
17. Casanova C, Cote C, Marin JM, et al. Distance and oxygen desaturation
during the 6-min walk test as predictors of long-term mortality in
patients with COPD. Chest. 2008;134:746-752.
18. Kohl Lde M, Signori LU, Ribeiro RA, et al. Prognostic value of the six-
minute walk test in end-stage renal disease life expectancy:
a prospective cohort study. Clinics (Sao Paulo). 2012;67:581-586.
19. Cooper R, Kuh D, Hardy R. Objectively measured physical capability
levels and mortality: systematic review and meta-analysis. BMJ. 2010;
341:c4467.
20. Leung AS, Chan KK, Sykes K, Chan KS. Reliability, validity, and
responsiveness of a 2-min walk test to assess exercise capacity of COPD
patients. Chest. 2006;130:119-125.
21. Li L, Chan L, Gerber LH. Validation of 2-minute walk test as a measure
of exercise tolerance and physical performance in patients with
chronic graft versus host disease. Arch Phys Med and Rehabil. 2008;89:
e28.
22. Norman K, Stobaus N, Gonzalez MC, et al. Hand grip strength: Outcome
predictor and marker of nutritional status. Clin Nutr. 2011;30:135-142.
23. Chang YT, Wu HL, Guo HR, et al. Handgrip strength is an independent
predictor of renal outcomes in patients with chronic kidney diseases.
Nephrol Dial Transplant. 2011;26:3588-3595.
24. Yoda M, Inaba M, Okuno S, et al. Poor muscle quality as a predictor of
high mortality independent of diabetes in hemodialysis patients. Bio-
med Pharmacother. 2012;66:266-270.
25. Kramer M, Heussner P, Herzberg PY, et al. Validation of the grip test
and human activity proﬁle for evaluation of physical performance
during the intermediate phase after allogeneic hematopoietic stem cell
transplantation. Support Care Cancer. 2013;21:1121-1129.
26. Rationale and design of the chronic GVHD cohort study: improving
outcomes assessment in chronic GVHD. Chronic GVHD Consortium.
Biol Blood Marrow Transplant. 2011 Aug;17(8):1114-11120. PMID:
21664473.
27. Mathiowetz V, Weber K, Volland G, Kashman N. Reliability and validity
of grip and pinch strength evaluations. J Hand Surg Am. 1984;9:
222-226.
28. Waters RL, Lunsford BR, Perry J, Byrd R. Energy-speed relationship of
walking: standard tables. J Orthop Res. 1988;6:215-222.
29. Lee S, Cook EF, Soiffer R, Antin JH. Development and validation of
a scale to measure symptoms of chronic graft-versus-host disease. Biol
Blood Marrow Transplant. 2002;8:444-452.
30. Daughton DM, Fix AJ, Kass I, et al. Maximum oxygen consumption and
the ADAPT quality-of-life scale. Arch Phys Med Rehabil. 1982;63:
620-622.
31. Herzberg PY, Heussner P, Mumm FH, et al. Validation of the Human
Activity Proﬁle Questionnaire in patients after allogeneic hematopoi-
etic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:
1707-1717.
32. McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in
bone marrow transplantation: development of the Functional Assess-
ment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale.
Bone Marrow Transplant. 1997;19:357-368.
33. Fehse N, Fehse B, Kroger N, et al. Inﬂuence of anti-thymocyte globulin
as part of the conditioning regimen on immune reconstitution
following matched related bone marrow transplantation. J Hematother
Stem Cell Res. 2003;12:237-242.
34. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form
Health Survey (SF-36). II. Psychometric and clinical tests of validity in
measuring physical and mental health constructs. Med Care. 1993;31:
247-263.
35. Ware JE, Kosinski M, Keller SD. SF-36 physical and mental health
summary scales: a user’s manual. Boston, MA: The Health Institute;
1994.
36. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual
and interpretation guide. Boston, MA: The Health Institute; 1993.
37. Ware JE, Dewey J. How to score version 2 of the SF-36 health survey.
Lincoln, RI: QualityMetric Incorporated; 2000.
38. Mathiowetz V, Kashman N, Volland G, et al. Grip and pinch strength:
normative data for adults. Arch Phys Med Rehabil. 1985;66:69-74.
